AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
Researchers unveil tumor-intrinsic role of PD-L1 in lung cancer progression and develop systematic method for discovering molecular glues that selectively degrade disease proteins, while advances in immunology research aim to improve care for immune-mediated inflammatory diseases.
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
Daily aspirin use does not prevent bowel cancer in the general population within 5-15 years and carries immediate bleeding risks, according to a new Cochrane review. However, long-term low-dose aspirin is associated with lower colorectal cancer risk in IBD patients.
Trellus Health announced a six-month extension of its contract with Johnson & Johnson to provide the Trellus Elevate platform for inflammatory bowel disease patients, driven by strong engagement and satisfaction metrics achieved during the pilot phase.
Teva and Sanofi reported positive 44-week data from the RELIEVE UCCD long-term extension study of duvakitug, showing durable efficacy in ulcerative colitis and Crohn's disease patients.
AbbVie reported stronger-than-expected Q4 revenue of $16.62 billion and EPS of $2.71, beating consensus estimates. The company advanced a toxin-based therapy in Phase 2 trials and filed suit challenging Medicare drug-price negotiations for Botox.
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07433946 |
Partial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBA |
RECRUITING | NA |
| NCT07392606 |
Validation of PET Questionnaire for Experience and Sustainability in Telemedicine. PET(Patient Experience in Telehealth) |
NOT_YET_RECRUITING | |
| NCT07385807 |
Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Outcomes With Patient With Inflammatory Bowel Disease |
RECRUITING | |
| NCT07380022 |
Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases. |
RECRUITING | NA |
| NCT07377188 |
Pregnancy and Inflammatory Bowel Disease |
RECRUITING | |
| NCT07300553 |
Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease |
RECRUITING | PHASE2 |
| NCT07271264 |
A Randomised Paired Design Study of Texture and Colour Enhancement Imaging (TXI) Versus High-definition White Light Endoscopy |
RECRUITING | NA |
| NCT07224113 |
Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD |
RECRUITING | |
| NCT07208214 |
Texture and Colour Enhancement Imaging (TXI) Versus Dye Chromoendoscopy for Dysplasia Detection in IBD Surveillance. |
NOT_YET_RECRUITING | NA |
| NCT07195123 |
Evaluation of the SMART IBD App in Pediatric IBD |
RECRUITING | NA |
